Safety and efficacy of inclisiran in treating hypercholesterolemia: A systemic review and meta-analysis

Abstract

Aims

To evaluate the efficacy and safety of inclisiran in the treatment of hypercholesterolemia.

Date synthesis

Randomized controlled trials comparing inclisiran with a placebo were searched until April 2024. Overall, 8 studies involving 4947 patients were included. Inclisiran reduced low-density lipoprotein cholesterol (mean difference [MD]: −46.95 %; 95 % confidence interval [CI]: −53.26 to −40.46; P < 0.05), proprotein convertase subtilisin/kexin type 9 (MD: −70.80 %; 95 % CI: −76.52 to −65.08; P < 0.05), serum total cholesterol (MD: −29.47 %; 95 % CI: −32.56 to −26.39; P < 0.05), non–high-density lipoprotein cholesterol (MD: −40.46 %; 95 % CI: −45.24 to −35.68; P < 0.05), apolipoprotein B (MD: −36.77 %; 95 % CI: −40.94 to −32.61; P < 0.05), and lipoprotein(a) (MD: −20.04 %; 95 % CI: −24.2 to −15.87; P < 0.05) levels but increased high-density lipoprotein cholesterol level (MD: 6.09 %; 95 % CI: 3.63 to 8.55; P < 0.05). The incidences of adverse events, serious adverse events, headache, nasopharyngitis, and muscular adverse reactions were not significantly different between the inclisiran and placebo groups. Inclisiran reduced the incidence of cardiovascular adverse reactions (odds ratio [OR] = 0.79; 95 % CI: 0.65 to 0.96; P = 0.02) and increased the incidence of injection-site reactions (OR = 4.79; 95 % CI: 2.18 to 10.52; P < 0.05).

Conclusion

Inclisiran is effective in treating hypercholesterolemia and has a good safety profile.